CLOSED
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinom. Track Concord Biotech Limited's live NSE:CONCORDBIO share price ₹1,391.00 (-1.94%), market cap ₹₹146B, P/E 48.0. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for CONCORDBIO — real-time NSE India stock intelligence.
Open
₹1,444.40
High
₹1,456.30
Low
₹1,389.00
Prev. Close
₹1,418.50
52W High
₹1,801.90
52W Low
₹987.00
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinom
Key Takeaway
Concord Biotech Limited is rated buy with a P/E of 48.0x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is Concord Biotech Limited fairly valued right now?
Because a P/E of 48.0x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting Concord Biotech Limited
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
326 Cr
Revenue
89 Cr
Net Profit
0%
ROE
0%
ROCE
28.98
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 831 | 998 | 1,180 | 1,046 | 1,055 |
| Net Profit | 240 | 308 | 372 | 261 | 260 |
| ROE (%) | — | — | — | 0.0% | 0.0% |
| EPS (₹) | — | — | — | 28.98 | 28.98 |
| Debt/Equity | — | — | — | 0.1 | 0.1 |